Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A. Stevenson M, et al. Among authors: archer r. Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350. Health Technol Assess. 2016. PMID: 27140438 Free PMC article. Review.
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, Archer RJ, Simpson EL, Hock ES, Young A, Scott DL. Stevenson MD, et al. J Rheumatol. 2017 Jul;44(7):973-980. doi: 10.3899/jrheum.160941. Epub 2017 Feb 15. J Rheumatol. 2017. PMID: 28202743 Free article. Review.
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Archer R, et al. Health Technol Assess. 2016 May;20(39):1-326. doi: 10.3310/hta20390. Health Technol Assess. 2016. PMID: 27220829 Free PMC article. Review.
Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A. Stevenson M, et al. Among authors: archer r. Health Technol Assess. 2016 Nov;20(35):611-614. doi: 10.3310/hta20350-c201611. Health Technol Assess. 2016. PMID: 27919316 Free article. No abstract available.
Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
Simpson EL, Ren S, Hock ES, Stevens JW, Binard A, Pers YM, Archer R, Paisley S, Stevenson MD, Herpin C, Ghabri S. Simpson EL, et al. Among authors: archer r. Int J Technol Assess Health Care. 2019 Jan;35(1):36-44. doi: 10.1017/S0266462318003628. Epub 2019 Feb 6. Int J Technol Assess Health Care. 2019. PMID: 30722803 Free article.
The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards.
Wailoo AJ, Stevenson M, Tosh J, Hernández M, Stevens JW, Archer R, Simpson E, Everson HE, Scott D, Young A, Paisley S, Williams K. Wailoo AJ, et al. Among authors: archer r. Value Health. 2014 Nov;17(7):A380. doi: 10.1016/j.jval.2014.08.2611. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200840 Free article. No abstract available.
437 results